Skip to main content

Table 1 Clinical and laboratory features of 123 Brazilian patients with primary gout

From: Nephrolithiasis in gout: prevalence and characteristics of Brazilian patients

 Value
Male gender115 (93.5%)
Skin color/race
 White102 (82.9%)
 Brown or Black14 (11.4%)
 Asian7 (5.7%)
Age (years)62.9 ± 09.4
Age at the onset of disease (years)44.9 ± 12.3
Duration of disease (years)18.2 ± 10.5
Tophi69 (56.1%)
Underexcretion of uric acid110 (89.4%)
Alcohol use disorder90 (73.2%)
 Current23 (18.7%)
 Past67 (54.5%)
Smoking history63 (51.2%)
 Current10 (8.1%)
 Past53 (43.1%)
Medication
 Allopurinol45 (36.6%)
 Benzbromarone76 (61.8%)
 Potassium citrate13 (10.6%)
 Colchicine32 (26.0%)
 Glucocorticoids7 (5.7%)
 NSAIDs64 (52.0%)
 Antidiabetic medication18 (14.6%)
 Antihypertensives92 (74.8%)
 Lipid-lowering medication25 (20.3%)
Serum creatinine (mg/dL)1.34 ± 0.55
Serum urea (mg/dL)44.1 ± 25.3
eGFR – CKD EPI (mL/min/1.73 m2)63.9 ± 21.7
Serum uric acid levels (mg/dL)7.13 ± 1.95
Uric acid clearance (mL/min)5.48 ± 3.91
 Uric acid clearance < 6 mL/min85 (69.1%)
Urinary uric acid excretion (g/24 h)0.53 ± 0.30
Serum glucose (mg/dL)105.7 ± 26.8
Serum total cholesterol (mg/dL)205.4 ± 49.4
Serum triglyceride (mg/dL)231.4 ± 399.6
Urinalysis
 pH5.79 ± 0.83
 Pyuria (>  10 leukocytes/HPF)6 (4.9%)
 Hematuria (>  3 erythrocytes/HPF)12 (9.8%)
 Significant proteinuria5 (4.1%)
  1. Data are expressed as the total (%) or the mean ± SD
  2. CKD – EPI Chronic Kidney Disease Epidemiology Collaboration equation
  3. eGFR estimated glomerular filtration rate
  4. HPF high-power field
  5. NSAIDs nonsteroidal anti-inflammatory drugs